PLX120-03 - De La Fuente, Macarena
-
Investigator:
Macarena De La Fuente
Email
Coordinator: Yaima de la Fuente
305-243-2441
IRB: 20150830
SDG: Neurological Cancer
Disease Site(s): Bones and Joints
Sponsor: Plexxikon
Enrolling Sites:
Sylvester
Title: A Phase 1/2a Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of PLX8394 in Patients with Advanced, Unresectable Solid Tumors
Eligibility Criteria - NCT02428712 *This information has been extracted from " www.clinicaltrials.gov"
Alliance A071401 - De La Fuente, Macarena
-
Investigator:
Macarena De La Fuente
Email
Coordinator: Nathalie Padron
+1 (305) 2439610
IRB: 20151026
SDG: Neurological Cancer
Disease Site(s): Brain and Nervous System
Sponsor: Alliance for Clinical Trials in Oncology
Enrolling Sites:
Deerfield
Kendall
SylvesterTitle: A071401: Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
Eligibility Criteria - NCT02523014 *This information has been extracted from " www.clinicaltrials.gov"
20180606 - De La Fuente Macarena
-
Investigator:
Macarena De La Fuente
Email
Coordinator: Nathalie Padron
+1 (305) 2439610
IRB: 20180606
SDG: Neurological Cancer
Disease Site(s): Brain and Nervous System
Sponsor: SCCC
Enrolling Sites:
Sylvester
Title: Non-invasive glioma characterization through molecular imaging
Eligibility Criteria - NCT03684109 *This information has been extracted from " www.clinicaltrials.gov"
GCAR-7213 - De La Fuente, Macarena
-
Investigator:
Macarena De La Fuente
Email
Coordinator: Yaima de la Fuente
305-243-2441
IRB: 20190401
SDG: Neurological Cancer
Disease Site(s): Brain and Nervous System
Sponsor: GCAR
Enrolling Sites:
Deerfield
Gables
Sylvester
UMHTitle: GBM AGILE MASTER PROTOCOL:GBM AGILE Global Adaptive Trial Master Protocol: An International, Seamless Phase II/III Response Adaptive Randomization Platform Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent Glioblastoma (GBM)
Eligibility Criteria - NCT03970447 *This information has been extracted from " www.clinicaltrials.gov"
20201293 - De La Fuente Macarena
-
Investigator:
Macarena De La Fuente
Email
Coordinator: Yaima de la Fuente
305-243-2441
IRB: 20201293
SDG: Neurological Cancer
Disease Site(s): Brain and Nervous System
Sponsor: Denovo
Enrolling Sites:
Deerfield
Gables
SylvesterTitle: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Enzastaurin Added to Temozolomide During and Following Radiation Therapy in Newly Diagnosed Glioblastoma Patients Who Possess the Novel Genomic Biomarker DGM1
Eligibility Criteria - NCT03776071 *This information has been extracted from " www.clinicaltrials.gov"
20210578 - De La Fuente Macarena
-
Investigator:
Macarena De La Fuente
Email
Coordinator: Brenda Obana
IRB: 20210578
SDG: Neurological Cancer
Disease Site(s): Brain and Nervous System
Sponsor: Pyramid Biosciences
Enrolling Sites:
Sylvester
Title: A Phase 1/2 Study of PBI-200 in Subjects With NTRK-Fusion-Positive Advanced or Metastatic Solid Tumors
Eligibility Criteria - NCT04901806 *This information has been extracted from " www.clinicaltrials.gov"
20210682 - De La Fuente Macarena
-
Investigator:
Macarena De La Fuente
Email
Coordinator: Yaima de la Fuente
305-243-2441
IRB: 20210682
SDG: Neurological Cancer
Disease Site(s): Brain and Nervous System
Sponsor: ETCTN
Enrolling Sites:
Deerfield
Gables
Plantation
SylvesterTitle: A Phase 2 Study of the PARP Inhibitor Olaparib (AZD2281) in IDH1 and IDH2 Mutant Advanced Solid Tumors
Eligibility Criteria - NCT03212274 *This information has been extracted from " www.clinicaltrials.gov"
20210950 - De La Fuente Macarena
-
Investigator:
Macarena De La Fuente
Email
Coordinator:
IRB: 20210950
SDG: Neurological Cancer
Disease Site(s): Sponsor: SCCC
Enrolling Sites:
Sylvester
Title: Olutasidenib (FT-2102) Treatment Plan for a Patient with an Advanced Solid Tumor or Glioma with an IDH1 Mutation
A071601 - Heros, Deborah
-
Investigator:
Deborah Heros
Email
Coordinator: Alain Fernandez Marrero
+1 (305) 2439553 x9553
IRB: 20180772
SDG: Neurological Cancer
Disease Site(s): Brain and Nervous System
Sponsor: Alliance for Clinical Trials in Oncology
Enrolling Sites:
Sylvester
Title: A071601: Phase II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas
Eligibility Criteria - NCT03224767 *This information has been extracted from " www.clinicaltrials.gov"
20200502 - Heros Deborah
-
Investigator:
Deborah Heros
Email
Coordinator: Nathalie Padron
+1 (305) 2439610
IRB: 20200502
SDG: Neurological Cancer
Disease Site(s): Multiple
Sponsor: Alliance for Clinical Trials in Oncology
Enrolling Sites:
Sylvester
UMHTitle: Genomically-Guided Treatment Trial in Brain Metastases
Eligibility Criteria - NCT03994796 *This information has been extracted from " www.clinicaltrials.gov"
EAF151 - Heros, Deborah
-
Investigator:
Deborah Heros
Email
Coordinator: Nathalie Padron
+1 (305) 2439610
IRB: 20200503
SDG: Neurological Cancer
Disease Site(s): Brain and Nervous System
Sponsor: ECOG
Enrolling Sites:
Deerfield
Gables
Sylvester
UMHTitle: Change in Relative Cerebral Blood Volume as a Biomarker for Early Response to Bevacizumab in Patients With Recurrent Glioblastoma
Eligibility Criteria - NCT03115333 *This information has been extracted from " www.clinicaltrials.gov"
NRG-BN003 - Mellon, Eric
-
Investigator:
Eric Mellon
Email
Coordinator:
IRB: 20170631
SDG: Neurological Cancer
Disease Site(s): Brain and Nervous System
Sponsor: NRG
Enrolling Sites:
Deerfield
Gables
JMH
SylvesterTitle: NRG-BN003:Phase III Trial Of Observation Versus Irradiation For A Gross Totally Resected Grade II Meningioma
Eligibility Criteria - NCT03180268 *This information has been extracted from " www.clinicaltrials.gov"
CCTG CE.7 - Mellon, Eric
-
Investigator:
Eric Mellon
Email
Coordinator: Lilly Sanchez
+1 (305) 2430974
IRB: 20190176
SDG: Neurological Cancer
Disease Site(s): Brain and Nervous System
Sponsor: CCTG
Enrolling Sites:
Deerfield
Gables
Plantation
SylvesterTitle: CCTG CE.7: A Phase III Trial of Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or More Brain Metastases
Eligibility Criteria - NCT03550391 *This information has been extracted from " www.clinicaltrials.gov"
20191167 - Mellon Eric
-
Investigator:
Eric Mellon
Email
Coordinator:
IRB: 20191167
SDG: Neurological Cancer
Disease Site(s): Brain and Nervous System
Sponsor: Alliance for Clinical Trials in Oncology
Enrolling Sites:
Deerfield
Gables
Sylvester
UMHTitle: Phase III Trial of Post-Surgical Single Fraction Stereotactic Radiosurgery (SRS) Compared With Fractionated SRS for Resected Metastatic Brain Disease
Eligibility Criteria - NCT04114981 *This information has been extracted from " www.clinicaltrials.gov"
20210335 - Mellon Eric
-
Investigator:
Eric Mellon
Email
Coordinator:
IRB: 20210335
SDG: Neurological Cancer
Disease Site(s): Brain and Nervous System
Sponsor: SCCC
Enrolling Sites:
Deerfield
Gables
SylvesterTitle: Pilot trial of spectroscopic MRI-guided, dose-escalated proton radiation therapy and bevacizumab for recurrent glioblastoma
Eligibility Criteria - NCT05284643 *This information has been extracted from " www.clinicaltrials.gov"
20210376 - Mellon Eric
-
Investigator:
Eric Mellon
Email
Coordinator:
IRB: 20210376
SDG: Neurological Cancer
Disease Site(s): Brain and Nervous System
Sponsor: NRG
Enrolling Sites:
Deerfield
Gables
SylvesterTitle: Phase III Trial of Salvage Stereotactic Radiosurgery (SRS) or SRS + Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for First or Second Distant Brain Relapse After Upfront SRS with Brain Metastasis Velocity >/= 4 Brain Metastases/Year
Eligibility Criteria - NCT04588246 *This information has been extracted from " www.clinicaltrials.gov"